Temozolomide (Temaccord) 5 mg capsules: Supply issue
Due to a shipping delay, Temaccord 5 mg capsules will be temporarily out of stock during July (Pharmacode: 2388278)
On this page
Affected product
Due to a shipping delay and higher than usual demand, the supplier will run out of the following product during July.
- Chemical: Temozolomide
- Presentation: Cap 5 mg
- Brand: Temaccord
- Pharmacode: 2388278
- Subsidy: $9.13
- Measure / Qty: per 5
Only the 5 mg capsules are affected by this issue, all other presentations remain available.
Community Schedule Listing(external link)
HML Schedule Listing(external link)
People who take Temaccord 5 mg capsules
From 1 July, you may receive an alternative product called Temozolomide (Devatis). This is a different brand of the same medicine you usually receive.
Same active ingredient in the same amount
The Devatis brand contains the same active ingredient in the same amount as the New Zealand approved brand you usually take (Temaccord).
We're sorry. We know changing brands of medicine can be disruptive. We have done this so you can continue to access your medicine.
Not reviewed by Medsafe
This medicine has not been reviewed by Medsafe for use in New Zealand. However, it has been approved for use in other countries. Your prescriber will discuss this with you before they prescribe it. You can read more information about unapproved medicine on the Healthify website.
Unapproved medicines | Healthify.nz(external link)
Alternative product funded 1 July 2026
We have listed an alternative product which has not been reviewed by Medsafe. It will need to be dispensed and supplied in line with section 29A of the Medicines Act.
- Chemical: Temozolomide
- Presentation: Cap 5 mg
- Brand: Temozolomide (Devatis)
- Pharmacode: 2733188
- Subsidy: $12.70
- Measure / Qty: per 5
Prescribing and supplying an unapproved medicine
Section 29A of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people when there is supply issue affecting the registered brand.
We know supplying an unapproved medicine is not ideal. In this case, however, this will allow people to continue to access an appropriate treatment.
We apologise for any inconvenience this causes.
What patients need to know about unapproved medicines – Healthify website(external link)
Flyer to support pharmacists' conversations with patients
- General Supply Issue A5 Flier [PDF 111 KB]
Expected resupply late July 2026
The supplier expects the next shipment of Temaccord to arrive during July 2026.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)